secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K/A
Filed at:   2023-11-22T23:59:59+00:00
Accession:  0001104659-23-120731
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome files Morphimmune historical financials: 2022 net loss $7.5M, cash $7.2M
--------------------------------------------------------------------------------

- Morphimmune 2022 net loss of $7.5M (2021: $2.8M); accumulated deficit $11.2M as of Dec 31, 2022.
- As of Dec 31, 2022, cash $7.2M, total assets $7.3M, total liabilities $0.8M.
- R&D expense $4.2M in 2022 (2021: $0.5M); G&A $3.3M (2021: $1.6M).
- Merger closed Sep 29, 2023; pro forma combined financials filed as Exhibit 99.3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923120731/0001104659-23-120731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923120731/tm2330767d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-120731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer